Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 9/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.42 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.42 |
| ▸ | DUT | P33316 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | AHR | P35869 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16214813 | 0.97 | KIF11 (0.50) | KIF11KCNH2SLC6A1SLC6A11DUT | |
| SCHEMBL841606 | 0.87 | DUT (0.48) | KIF11SLC6A1DUTCYP2C9TSHR | |
| SCHEMBL15730746 | 0.87 | KIF11 (0.43) | KIF11KCNH2SLC6A1SLC6A11DUT | |
| SCHEMBL15281845 | 0.87 | KIF11 (0.49) | KIF11KCNH2SLC6A1SLC6A11TSHR | |
| SCHEMBL9508740 | 0.87 | KIF11 (0.49) | KIF11KCNH2SLC6A1SLC6A11 | |
| SCHEMBL3490250 | 0.87 | KIF11 (0.49) | KIF11KCNH2SLC6A1SLC6A11TSHR | |
| SCHEMBL13881801 | 0.86 | KIF11 (0.50) | KIF11KCNH2SLC6A1SLC6A11 | |
| SCHEMBL15709164 | 0.86 | KIF11 (0.50) | KIF11KCNH2SLC6A1SLC6A11 | |
| SCHEMBL2897015 | 0.85 | KIF11 (0.61) | KIF11KCNH2SLC6A1SLC6A11CYP2C9 | |
| SCHEMBL1263156 | 0.85 | KIF11 (0.61) | KIF11KCNH2SLC6A1SLC6A11CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100055168-A1 | CATIONIC LIPIDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100055168-A1 | CATIONIC LIPIDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100055168-A1 | CATIONIC LIPIDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-03-04 | — | — | US | disclosed |
| US-20090285881-A1 | CATIONIC LIPIDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-11-19 | — | — | US | disclosed |
| US-20090285881-A1 | CATIONIC LIPIDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-11-19 | — | — | US | disclosed |
| US-20090285881-A1 | CATIONIC LIPIDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-11-19 | — | — | US | disclosed |
| WO-2009129385-A1 | CATIONIC LIPIDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-10-22 | — | — | WO | disclosed |
| WO-2009129385-A1 | CATIONIC LIPIDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090285881-A1 | CATIONIC LIPIDS AND USES THEREOF | LIPA, SGMS2, SGMS1 | KIF11 4511/4885KCNH2 2472/4885SLC6A1 1141/4885 |
| US-20100055168-A1 | CATIONIC LIPIDS AND USES THEREOF | LIPA, SGMS2, SGMS1 | KIF11 4511/4885KCNH2 2472/4885SLC6A1 1141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.